Selected research
Industry Research
Rituximab Injection Industry Research Report 2026
Market perspective
The global Rituximab Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Rituximab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Rituximab Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Rituximab Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Rituximab Injection include Innovent Biologics, Roche, Pfizer, Fosun-Pharmaceutical, Shanghai Henlius Biotech, Amgen, Zenotech Laboratories, TRPharma and Probiomed, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Rituximab Injection market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rituximab Injection Market by Company
Innovent Biologics
Roche
Pfizer
Fosun-Pharmaceutical
Shanghai Henlius Biotech
Amgen
Zenotech Laboratories
TRPharma
Probiomed
Lexicare Pharma
Kavya Pharma
Intas Pharmaceuticals
Hetero Group
Healthiza Lifescience
Dr Reddy’s Laboratories
Celltrion
Cadila Pharmaceuticals
Rituximab Injection Segment by Type
100 ml
500 ml
Rituximab Injection Segment by Application
Hospitals
Clinics
Others
Rituximab Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rituximab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rituximab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rituximab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rituximab Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rituximab Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rituximab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 100 ml
- 500 ml
Applications
- Hospitals
- Clinics
- Others
Companies covered
- Innovent Biologics
- Roche
- Pfizer
- Fosun-Pharmaceutical
- Shanghai Henlius Biotech
- Amgen
- Zenotech Laboratories
- TRPharma
- Probiomed
- Lexicare Pharma
- Kavya Pharma
- Intas Pharmaceuticals
- Hetero Group
- Healthiza Lifescience
- Dr Reddy’s Laboratories
- Celltrion
- Cadila Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Rituximab Injection Market Size (2021-2032)
- 2.2.2 Global Rituximab Injection Sales (2021-2032)
- 2.2.3 Global Rituximab Injection Market Average Price (2021-2032)
- 2.3 Rituximab Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 100 ml
- 2.3.3 500 ml
- 2.4 Rituximab Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Rituximab Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Rituximab Injection Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Rituximab Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Rituximab Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Rituximab Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Rituximab Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Rituximab Injection, Product Type & Application
- 3.8 Global Manufacturers of Rituximab Injection, Established Date
- 3.9 Global Rituximab Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Innovent Biologics
- 4.1.1 Innovent Biologics Company Information
- 4.1.2 Innovent Biologics Business Overview
- 4.1.3 Innovent Biologics Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Innovent Biologics Rituximab Injection Product Portfolio
- 4.1.5 Innovent Biologics Recent Developments
- 4.2 Roche
- 4.2.1 Roche Company Information
- 4.2.2 Roche Business Overview
- 4.2.3 Roche Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Roche Rituximab Injection Product Portfolio
- 4.2.5 Roche Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Rituximab Injection Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 Fosun-Pharmaceutical
- 4.4.1 Fosun-Pharmaceutical Company Information
- 4.4.2 Fosun-Pharmaceutical Business Overview
- 4.4.3 Fosun-Pharmaceutical Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Fosun-Pharmaceutical Rituximab Injection Product Portfolio
- 4.4.5 Fosun-Pharmaceutical Recent Developments
- 4.5 Shanghai Henlius Biotech
- 4.5.1 Shanghai Henlius Biotech Company Information
- 4.5.2 Shanghai Henlius Biotech Business Overview
- 4.5.3 Shanghai Henlius Biotech Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Shanghai Henlius Biotech Rituximab Injection Product Portfolio
- 4.5.5 Shanghai Henlius Biotech Recent Developments
- 4.6 Amgen
- 4.6.1 Amgen Company Information
- 4.6.2 Amgen Business Overview
- 4.6.3 Amgen Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Amgen Rituximab Injection Product Portfolio
- 4.6.5 Amgen Recent Developments
- 4.7 Zenotech Laboratories
- 4.7.1 Zenotech Laboratories Company Information
- 4.7.2 Zenotech Laboratories Business Overview
- 4.7.3 Zenotech Laboratories Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zenotech Laboratories Rituximab Injection Product Portfolio
- 4.7.5 Zenotech Laboratories Recent Developments
- 4.8 TRPharma
- 4.8.1 TRPharma Company Information
- 4.8.2 TRPharma Business Overview
- 4.8.3 TRPharma Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 TRPharma Rituximab Injection Product Portfolio
- 4.8.5 TRPharma Recent Developments
- 4.9 Probiomed
- 4.9.1 Probiomed Company Information
- 4.9.2 Probiomed Business Overview
- 4.9.3 Probiomed Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Probiomed Rituximab Injection Product Portfolio
- 4.9.5 Probiomed Recent Developments
- 4.10 Lexicare Pharma
- 4.10.1 Lexicare Pharma Company Information
- 4.10.2 Lexicare Pharma Business Overview
- 4.10.3 Lexicare Pharma Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Lexicare Pharma Rituximab Injection Product Portfolio
- 4.10.5 Lexicare Pharma Recent Developments
- 4.11 Kavya Pharma
- 4.11.1 Kavya Pharma Company Information
- 4.11.2 Kavya Pharma Business Overview
- 4.11.3 Kavya Pharma Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Kavya Pharma Rituximab Injection Product Portfolio
- 4.11.5 Kavya Pharma Recent Developments
- 4.12 Intas Pharmaceuticals
- 4.12.1 Intas Pharmaceuticals Company Information
- 4.12.2 Intas Pharmaceuticals Business Overview
- 4.12.3 Intas Pharmaceuticals Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Intas Pharmaceuticals Rituximab Injection Product Portfolio
- 4.12.5 Intas Pharmaceuticals Recent Developments
- 4.13 Hetero Group
- 4.13.1 Hetero Group Company Information
- 4.13.2 Hetero Group Business Overview
- 4.13.3 Hetero Group Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Hetero Group Rituximab Injection Product Portfolio
- 4.13.5 Hetero Group Recent Developments
- 4.14 Healthiza Lifescience
- 4.14.1 Healthiza Lifescience Company Information
- 4.14.2 Healthiza Lifescience Business Overview
- 4.14.3 Healthiza Lifescience Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Healthiza Lifescience Rituximab Injection Product Portfolio
- 4.14.5 Healthiza Lifescience Recent Developments
- 4.15 Dr Reddy’s Laboratories
- 4.15.1 Dr Reddy’s Laboratories Company Information
- 4.15.2 Dr Reddy’s Laboratories Business Overview
- 4.15.3 Dr Reddy’s Laboratories Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Dr Reddy’s Laboratories Rituximab Injection Product Portfolio
- 4.15.5 Dr Reddy’s Laboratories Recent Developments
- 4.16 Celltrion
- 4.16.1 Celltrion Company Information
- 4.16.2 Celltrion Business Overview
- 4.16.3 Celltrion Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Celltrion Rituximab Injection Product Portfolio
- 4.16.5 Celltrion Recent Developments
- 4.17 Cadila Pharmaceuticals
- 4.17.1 Cadila Pharmaceuticals Company Information
- 4.17.2 Cadila Pharmaceuticals Business Overview
- 4.17.3 Cadila Pharmaceuticals Rituximab Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Cadila Pharmaceuticals Rituximab Injection Product Portfolio
- 4.17.5 Cadila Pharmaceuticals Recent Developments
5 Global Rituximab Injection Market Scenario by Region
- 5.1 Global Rituximab Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Rituximab Injection Sales by Region: 2021-2032
- 5.2.1 Global Rituximab Injection Sales by Region: 2021-2026
- 5.2.2 Global Rituximab Injection Sales by Region: 2027-2032
- 5.3 Global Rituximab Injection Revenue by Region: 2021-2032
- 5.3.1 Global Rituximab Injection Revenue by Region: 2021-2026
- 5.3.2 Global Rituximab Injection Revenue by Region: 2027-2032
- 5.4 North America Rituximab Injection Market Facts & Figures by Country
- 5.4.1 North America Rituximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Rituximab Injection Sales by Country (2021-2032)
- 5.4.3 North America Rituximab Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Rituximab Injection Market Facts & Figures by Country
- 5.5.1 Europe Rituximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Rituximab Injection Sales by Country (2021-2032)
- 5.5.3 Europe Rituximab Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Rituximab Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Rituximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Rituximab Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Rituximab Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Rituximab Injection Market Facts & Figures by Country
- 5.7.1 South America Rituximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Rituximab Injection Sales by Country (2021-2032)
- 5.7.3 South America Rituximab Injection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Rituximab Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Rituximab Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Rituximab Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Rituximab Injection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Rituximab Injection Sales by Type (2021-2032)
- 6.1.1 Global Rituximab Injection Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Rituximab Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Rituximab Injection Revenue by Type (2021-2032)
- 6.2.1 Global Rituximab Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Rituximab Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Rituximab Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Rituximab Injection Sales by Application (2021-2032)
- 7.1.1 Global Rituximab Injection Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Rituximab Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Rituximab Injection Revenue by Application (2021-2032)
- 7.2.1 Global Rituximab Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Rituximab Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Rituximab Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Rituximab Injection Value Chain Analysis
- 8.1.1 Rituximab Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Rituximab Injection Production Mode & Process
- 8.2 Rituximab Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Rituximab Injection Distributors
- 8.2.3 Rituximab Injection Customers
9 Global Rituximab Injection Analyzing Market Dynamics
- 9.1 Rituximab Injection Industry Trends
- 9.2 Rituximab Injection Industry Drivers
- 9.3 Rituximab Injection Industry Opportunities and Challenges
- 9.4 Rituximab Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst